OTCMKTS:BPMUF Basilea Pharmaceutica (BPMUF) Stock Forecast, Price & News $50.00 0.00 (0.00%) (As of 09/21/2023 ET) Add Compare Share Share Today's Range$50.00▼$50.0050-Day Range$50.00▼$50.0052-Week Range$50.00▼$50.00VolumeN/AAverage VolumeN/AMarket Capitalization$592.50 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileAnalyst RatingsChartCompetitorsHeadlinesShort InterestProfileAnalyst RatingsChartCompetitorsHeadlinesShort Interest About Basilea Pharmaceutica (OTCMKTS:BPMUF) StockBasilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. It offers Cresemba, an intravenous and oral azole antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union, as well as in Phase III clinical trials for invasive fungal infections in Japan. The company also provides Zevtera, an antibiotic for the treatment of community and hospital-acquired pneumonia, as well as in Phase III clinical trials for the treatment of acute bacterial skin and skin structure infections, and Staphylococcus aureus bacteremia. In addition, it engages in developing, a small-molecule inhibitor of DXR, as well as in phase ½ clinical trial for urothelial and gastric cancer; and Lisavanbulin, a tumor checkpoint controller drug. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Allschwil, Switzerland.Read More BPMUF Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BPMUF Stock News HeadlinesAugust 15, 2023 | finance.yahoo.comBasilea reports strong revenue and profit growth in first half-year 2023August 4, 2023 | markets.businessinsider.comBasilea Pharma Submits NDA For Antibiotic CeftobiproleSeptember 22, 2023 | Behind the Markets (Ad)Laser breakthrough could send stock soaring 2,467%Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...August 4, 2023 | finance.yahoo.comBasilea announces submission of a New Drug Application to the US Food and Drug Administration for its antibiotic ceftobiproleJune 8, 2023 | finance.yahoo.comContinued strong Cresemba® (isavuconazole) sales by Pfizer trigger USD 26 million sales milestone payments to BasileaApril 18, 2023 | finance.yahoo.comBasilea provides update on New Drug Application to the US Food and Drug Administration for antibiotic ceftobiproleFebruary 14, 2023 | markets.businessinsider.comBasilea Pharmaceutica Posts FY ProfitFebruary 14, 2023 | finance.yahoo.comBasilea reports strong financial results 2022 based on successful implementation of new strategySeptember 22, 2023 | Chaikin Analytics (Ad)Buy This Stock for AI Tidal Wave (not NVDA)The internet boom made more millionaires than any tech - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.February 7, 2023 | finance.yahoo.comContinued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers second sales milestone payment to Basilea from PfizerJanuary 24, 2023 | markets.businessinsider.comBasilea Pharma Expects Net Profit In FY22January 24, 2023 | finance.yahoo.comBasilea reports preliminary operating profit for 2022, significantly above guidanceJanuary 11, 2023 | finance.yahoo.comBasilea reports preliminary 2022 revenues, exceeding guidance, and provides portfolio updateJanuary 9, 2023 | finance.yahoo.comContinued strong Cresemba® (isavuconazole) sales by Astellas in the U.S. trigger CHF 20 million sales milestone payment to BasileaDecember 28, 2022 | finance.yahoo.comBasilea announces repayment of 2022 convertible bondsDecember 23, 2022 | finance.yahoo.comBasilea announces regulatory approval of antifungal Cresemba® (isavuconazole) in JapanDecember 19, 2022 | finance.yahoo.comBasilea announces transition milestone for oncology asset BAL0891, triggering milestone payment of USD 4 million by SillaJenDecember 14, 2022 | finance.yahoo.comHere's Why Momentum in Basilea Pharmaceutica AG (BPMUF) Should Keep goingDecember 9, 2022 | finance.yahoo.comIs Basilea Pharmaceutica (BPMUF) Outperforming Other Medical Stocks This Year?November 28, 2022 | finance.yahoo.comHere's What Could Help Basilea Pharmaceutica AG (BPMUF) Maintain Its Recent Price StrengthNovember 2, 2022 | nasdaq.comBasilea Pharma To Sell Preclinical CLK Kinase Inhibitors To Twentyeight-SevenTherapeuticsNovember 2, 2022 | finance.yahoo.comBasilea announces sale of preclinical oncology program to Twentyeight-Seven TherapeuticsOctober 13, 2022 | finance.yahoo.comBasilea announces late breaking presentation on the successfully completed ERADICATE phase 3 study with ceftobiprole in Staphylococcus aureus bacteremia (SAB) at IDWeek 2022October 8, 2022 | reuters.comBasilea Pharmaceutica AGSeptember 21, 2022 | finance.yahoo.comBasilea announces closing of CHF 75 million senior secured loan agreement with AthyriumSeptember 20, 2022 | finance.yahoo.comBasilea announces acquisition of rights for oncology asset BAL0891 by SillaJen and updates financial guidanceSeptember 8, 2022 | finance.yahoo.comBasilea announces sale of preclinical oncology program to Nodus OncologySee More Headlines Receive BPMUF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Basilea Pharmaceutica and its competitors with MarketBeat's FREE daily newsletter. Email Address BPMUF Company Calendar Today9/22/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:BPMUF CUSIPN/A CIKN/A Webwww.basilea.com Phone(161) 606-1111Fax41-61-606-1112Employees143Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio2.34 Quick Ratio2.02 Sales & Book Value Annual Sales$154.86 million Price / Sales3.83 Cash Flow$1.17 per share Price / Cash Flow42.69 Book Value($1.83) per share Price / Book-27.32Miscellaneous Outstanding Shares11,850,000Free FloatN/AMarket Cap$592.50 million OptionableNot Optionable Beta0.84 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. David Veitch (Age 58)Chief Exec. Officer Comp: $1.37MMr. Adesh Kaul (Age 49)Chief Financial Officer Dr. Gerrit Hauck Ph.D. (Age 59)Chief Technology Officer Dr. Laurenz Kellenberger Ph.D. (Age 56)Chief Scientific Officer Dr. Marc Engelhardt M.D. (Age 59)Chief Medical Officer Dr. Peer Nils SchroderHead of Corp. Communications & Investor RelationsMr. Damian Heller (Age 57)Gen. Counsel & Corp. Sec. Ms. Ursula Eberhardt (Age 61)Head of Global HR Mr. Mark Jones (Age 55)Head of Project Management & Preclinical Devel. Mr. Peter Bielmeier Ph.D. (Age 56)Head of Global Quality Management More ExecutivesKey CompetitorsEnliven TherapeuticsNASDAQ:ELVNAlpine Immune SciencesNASDAQ:ALPNDyne TherapeuticsNYSE:DYNAvid BioservicesNASDAQ:CDMOBicycle TherapeuticsNASDAQ:BCYCView All Competitors BPMUF Stock - Frequently Asked Questions Should I buy or sell Basilea Pharmaceutica stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Basilea Pharmaceutica in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" BPMUF shares. View BPMUF analyst ratings or view top-rated stocks. How have BPMUF shares performed in 2023? Basilea Pharmaceutica's stock was trading at $52.00 at the beginning of 2023. Since then, BPMUF stock has decreased by 3.8% and is now trading at $50.00. View the best growth stocks for 2023 here. Are investors shorting Basilea Pharmaceutica? Basilea Pharmaceutica saw a decline in short interest in August. As of August 31st, there was short interest totaling 276,400 shares, a decline of 9.2% from the August 15th total of 304,300 shares. Based on an average trading volume of 0 shares, the days-to-cover ratio is presently ∞ days. View Basilea Pharmaceutica's Short Interest. What is Basilea Pharmaceutica's stock symbol? Basilea Pharmaceutica trades on the OTCMKTS under the ticker symbol "BPMUF." How do I buy shares of Basilea Pharmaceutica? Shares of BPMUF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Basilea Pharmaceutica's stock price today? One share of BPMUF stock can currently be purchased for approximately $50.00. How much money does Basilea Pharmaceutica make? Basilea Pharmaceutica (OTCMKTS:BPMUF) has a market capitalization of $592.50 million and generates $154.86 million in revenue each year. How many employees does Basilea Pharmaceutica have? The company employs 143 workers across the globe. Does Basilea Pharmaceutica have any subsidiaries? The following companies are subsidiares of Basilea Pharmaceutica: Conec UK Limited.Read More How can I contact Basilea Pharmaceutica? Basilea Pharmaceutica's mailing address is Grenzacherstrasse 487, Basel V8, 4058. The official website for the company is www.basilea.com. The company can be reached via phone at (161) 606-1111, via email at investor_relations@basilea.com, or via fax at 41-61-606-1112. This page (OTCMKTS:BPMUF) was last updated on 9/22/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Basilea Pharmaceutica AG Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.